Quantcast
Last updated on April 20, 2014 at 14:04 EDT

Latest Cisplatin Stories

2012-02-02 22:53:31

The internet is awash with stories of how silver can be used to treat cancer. Now, lab tests have shown that it is as effective as the leading chemotherapy drug - and may have fewer side-effects. Results from the study at the University of Leeds, published in Dalton Transactions, show that particular silver compounds are as toxic to cancer cells as the platinum-based drug Cisplatin, which is widely used to treat a range of cancers. But the crucial difference is that silver is thought to...

2012-01-26 11:50:45

A select subgroup of advanced head and neck cancer patients treated with radiation therapy plus the chemotherapy drug cisplatin had more positive outcomes than patients treated with radiation therapy alone and continued to show positive results 10 years post-treatment, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM. Researchers analyzed two subgroups totaling 410 patients who had advanced head and neck cancer...

2012-01-26 10:05:23

Ovarian cancer is a major cause of death worldwide. Approximately 25,000 women will be diagnosed with ovarian cancer this year and 15,000 women will die from it in the United States alone. The novel anti-cancer drug diindolylmethane (DIM) has been shown in laboratory to inhibit the growth of ovarian cancer cells. New research published in BioMed Central's open access journal BMC Medicine has looked in detail at the action of DIM and showed that it works by blocking the activation and...

2011-11-21 23:17:15

Discovery opens a new targeting scheme for drug delivery that potentially would reduce toxic side effects An anti-cancer drug used extensively in chemotherapy binds pervasively to RNA -- up to 20-fold more than it does to DNA, a surprise finding that suggests new targeting approaches might be useful, according to University of Oregon researchers. Medical researchers have long known that cisplatin, a platinum compound used to fight tumors in nearly 70 percent of all human cancers,...

2011-11-15 05:00:00

HOBOKEN, N.J. and PHILADELPHIA, Nov. 15, 2011 /PRNewswire/ -- Niiki Pharma Inc. presented the results of preclinical combination studies of its lead product, NKP-1339, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics held in San Francisco, CA, November 12-16, 2011. The data were presented as a poster, titled "NKP-1339 synergistic activity in both in vitro and in vivo preclinical models highlights the therapeutic opportunity for NKP-1339...

2011-11-07 13:27:00

SILVER SPRING, Md., Nov. 7, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Erbitux (cetuximab) for use with chemotherapy to treat patients with late-stage (metastatic) head and neck cancer. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) Combined with chemotherapy, Erbitux extended the lives of those receiving the treatment combination compared with those receiving chemotherapy alone. Erbitux already is FDA-approved for certain types of...

2011-10-28 02:00:00

INDIANAPOLIS, Oct. 28, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the European Commission has granted approval for the use of ALIMTA® (pemetrexed for injection) as a single agent for continuation maintenance therapy in patients with a particular type of lung cancer, called advanced nonsquamous non-small cell lung cancer (NSCLC). The approval is based on clinical trial results showing an improvement in progression-free survival, as well as...

2011-09-26 12:00:00

INDIANAPOLIS, Sept. 26, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that a new subgroup analysis of data from the pivotal Phase III PARAMOUNT study showed that continuation maintenance therapy with ALIMTA(® )(pemetrexed for injection) also reduces the risk of disease progression in patients aged 70 years or older with advanced nonsquamous non-small cell lung cancer (NSCLC), the most common type of lung cancer. Results from the new analysis...

2011-09-26 07:00:00

INDIANAPOLIS, Sept. 26, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the use of ALIMTA® (pemetrexed for injection) as continuation maintenance therapy in patients with advanced nonsquamous non-small cell lung cancer (NSCLC). Positive opinions from the CHMP are reviewed by the European Commission, which then decides on...

2011-07-12 22:35:33

Researchers at The Pennsylvania State University College of Medicine, Hershey, Pennsylvania have discovered that a low dose of the opioid antagonist naltrexone (LDN) has an extraordinarily potent antitumor effect on human ovarian cancer in tissue culture and xenografts established in nude mice. When LDN is combined with chemotherapy, there is an additive inhibitory action on tumorigenesis. This discovery, reported in the July 2011 issue of Experimental Biology and Medicine, provides new...